skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Prevalence of antibodies against SARS‐CoV‐2 in the Norwegian population, August 2021

Influenza and other respiratory viruses, 2022-11, Vol.16 (6), p.1004-1013 [Peer Reviewed Journal]

2022 The Authors. published by John Wiley & Sons Ltd. ;COPYRIGHT 2022 John Wiley & Sons, Inc. ;2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;info:eu-repo/semantics/openAccess ;ISSN: 1750-2640 ;EISSN: 1750-2659 ;DOI: 10.1111/irv.13024 ;PMID: 35770841

Full text available

Citations Cited by
  • Title:
    Prevalence of antibodies against SARS‐CoV‐2 in the Norwegian population, August 2021
  • Author: Tunheim, Gro ; Rø, Gunnar Øyvind Isaksson ; Chopra, Adity ; Aase, Audun ; Kran, Anne‐Marte Bakken ; Vaage, John Torgils ; Lund‐Johansen, Fridtjof ; Hungnes, Olav
  • Subjects: Antibodies ; Coronaviruses ; COVID-19 ; COVID-19 vaccines ; Epidemics ; Flow cytometry ; Immunization ; Immunoglobulin G ; infection ; Infections ; Laboratories ; Medical research ; Medicine, Experimental ; nucleocapsid ; Original ; Pandemics ; Protein binding ; Proteins ; SARS‐CoV‐2 ; Serology ; seroprevalence ; Severe acute respiratory syndrome ; Severe acute respiratory syndrome coronavirus 2 ; Spike protein ; Vaccination ; Viral diseases
  • Is Part Of: Influenza and other respiratory viruses, 2022-11, Vol.16 (6), p.1004-1013
  • Description: Background One year into the COVID‐19 pandemic, the cumulative number of confirmed COVID‐19 cases in Norway was still low. In January 2021, when the Norwegian COVID‐19 vaccination campaign started, the national seroprevalence estimate of SARS‐CoV‐2 antibodies was 3.2%. We have conducted a nationwide cross‐sectional study in August 2021 to investigate the overall prevalence of SARS‐CoV‐2 antibodies in Norway after 8 months of COVID‐19 mass vaccination and a third wave of SARS‐CoV‐2 infection. Methods Residual sera were collected from laboratories across Norway in August 2021. In IgG antibodies against the spike protein, the spike receptor binding domain (RBD) and the nucleocapsid protein of SARS‐CoV‐2 were measured by a bead‐based flow cytometric assay. Results In total, 1926 residual sera were collected from individuals aged 0–98 years; 55.1% were from women. The overall national estimated seroprevalence from vaccination and/or infection was 62.6% (credible interval [CrI] 60.1%–65.2%) based on having antibodies against both spike and RBD. Estimated seroprevalence increased with age. Among all samples, 11.7% had antibodies against nucleocapsid. For unvaccinated children <12 years, the seroprevalence estimate due to SARS‐CoV‐2 infection was 12.5% (95% CrI 9.3%–16.1%). Of seropositive samples from the unvaccinated children, 31.9% lacked anti‐nucleocapsid antibodies. Conclusions The high overall SARS‐CoV‐2 seroprevalence estimates are in line with Norwegian registry data. Vaccination, not infection, contributed the most to the high seroprevalence in August 2021. Lack of antibodies against nucleocapsid should not automatically be interpreted as absence of previous infection as this could lead to underestimation of COVID‐19 cases in seroprevalence studies.
  • Publisher: Chichester: John Wiley & Sons, Inc
  • Language: English;Norwegian
  • Identifier: ISSN: 1750-2640
    EISSN: 1750-2659
    DOI: 10.1111/irv.13024
    PMID: 35770841
  • Source: NORA Norwegian Open Research Archives
    PubMed Central
    Wiley Online Library Open Access
    Coronavirus Research Database
    ProQuest Central
    DOAJ Directory of Open Access Journals
Back to results list
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait